Results for this period
Interim period (second quarter)1 November 2025 to 30 April 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating profit increased due to cost reductions, primarily in selling, general and administrative expenses. The number of contract processing cases declined from 10,303 to 10,114, and sales of contract processing services, cosmetics and other products decreased, while sales of medical institution support services and medical equipment increased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 November 2025 to 30 April 2026 |
| Net Sales | ¥1,775 million (YoY -2.5%) |
| Operating profit | ¥125 million (YoY +636.3%) |
| Ordinary income | ¥115 million (YoY +510.4%) |
| Profit attributable to owners of the parent | ¥71 million (YoY +537.2%) |
| Net income per share | ¥3.59 |
| Equity ratio | End of the current fiscal period 84.2 / End of previous period 84 |
| Total assets | ¥6,984 million |
| Net assets | ¥5,992 million |
| Cash flows from operating activities | ¥287,837 thousand |
| Cash flows from investing activities | ¥-103,020 thousand |
| Cash flows from financing activities | ¥-110,572 thousand |
| Cash and cash equivalents at end of period | ¥4,786,531 thousand |
| Full-year earnings forecast | Net Sales ¥3,418 million (YoY -7.9%) / Operating profit ¥-170 million / Ordinary income ¥-164 million / Net income ¥-136 million |
| Annual Dividend Forecast | ¥5 → ¥0（-100.0%） |
| Depreciation and amortization | ¥88,284 thousand |
| Impairment loss | Amount ¥11,665 thousand / Subject assets Not disclosed |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on reversal of subscription rights to shares / Amount ¥6,766 thousand / Extraordinary loss Item Impairment Losses / Amount ¥11,665 thousand, Item Loss on store closures / Amount ¥2,443 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for investors and analysts) |
| Issued Shares at Period-End | 19,847,779 |
| Treasury Shares at Period-End | 580 |
| Factors Behind Changes in Business Performance | Operating profit increased due to cost reductions, primarily in selling, general and administrative expenses. The number of contract processing cases declined from 10,303 to 10,114, and sales of contract processing services, cosmetics and other products decreased, while sales of medical institution support services and medical equipment increased. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company optimized the allocation of management resources and implemented cost reductions, primarily in selling, general and administrative expenses. On the sales side, growth was sluggish in the number of contracted cases per medical institution, the number of contract processing cases declined, and cosmetics sales under the BtoB model decreased, while sales of medical institution support services and medical equipment increased.